<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">Mol Med</journal-id><journal-title-group><journal-title>Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1076-1551</issn><issn pub-type="epub">1528-3658</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39984834</article-id><article-id pub-id-type="pmc">PMC11846196</article-id>
<article-id pub-id-type="publisher-id">1127</article-id><article-id pub-id-type="doi">10.1186/s10020-025-01127-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>CYFIP1 coordinate with RNMT to induce osteosarcoma cuproptosis via AURKAIP1 m7G modification</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Zili</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Ziyi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Yizhe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiangyao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Luo</surname><given-names>Wei</given-names></name><address><email>luoweixy@csu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Orthopaedics, Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, Hunan 410008 P.R. China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05c1yfj14</institution-id><institution-id institution-id-type="GRID">grid.452223.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 7615</institution-id><institution>National Clinical Research Center for Geriatric Disorders, </institution><institution>Xiangya Hospital, </institution></institution-wrap>Changsha, Hunan 410008 P.R. China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Orthopaedics, The Second Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, Hunan 410011 P.R. China </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>31</volume><elocation-id>74</elocation-id><history><date date-type="received"><day>6</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025, corrected publication 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Osteosarcoma (OS) presents challenges due to its genomic instability and complexity, necessitating investigation into its oncogenesis and progression mechanisms. Recent studies have implicated m7G, a post-transcriptional modification, in the development of various cancers. However, research on m7G modification in OS remains limited. This study aimed to explore the impact of m7G modification in OS, focusing on the role and mechanism of CYFIP1, a member of m7G cap binding complexes. Our findings demonstrated prominent anti-OS effects of CYFIP1 in vitro and vivo. Mechanistically, CYFIP1 collaborated with RNMT to induce the m7G methylation of AURKAIP1 mRNA, which resulted in the stability and the increasing translation of AURKAIP1 mRNA. AURKAIP1, a kind of mitochondrial small ribosomal subunit protein, exhibited increased expression, leading to the dysregulation of mitochondrial translation. This, in turn, caused an increase in the expression of FDX1, eventually triggering cuproptosis in OS cells and repressing OS occurrence and progression. In summary, our study identified the CYFIP1/RNMT/AURKAIP1/FDX1 axis as a potential therapeutic target for OS. These insights contribute to OS research and may guide the development of novel treatments for this challenging disease.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s10020-025-01127-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>AURKAIP1</kwd><kwd>Cuproptosis</kwd><kwd>CYFIP1</kwd><kwd>FDX1</kwd><kwd>m7G modification</kwd><kwd>RNMT</kwd></kwd-group><funding-group><award-group><funding-source><institution>the Provincial Science and Technology Innovation Plan Project of Hunan</institution></funding-source><award-id>2023SK2023</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Feinstein Institute for Medical Research 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par19">Osteosarcoma (OS) stands as the most prevalent primary bone malignancy, predominantly affecting the adolescents(Ritter et al. <xref ref-type="bibr" rid="CR1">2010</xref>). Substantial progress in the realm of multidisciplinary therapies, encompassing surgical interventions, chemotherapy, radiotherapy, and targeted therapies, have notably improved the 5-year survival rates among primary OS patients while the prognosis for individuals afflicted with metastatic or recurrent OS remains disconcertingly dismal(Ritter et al. <xref ref-type="bibr" rid="CR1">2010</xref>; Gill and Gorlick <xref ref-type="bibr" rid="CR2">2021</xref>; Meltzer and Helman <xref ref-type="bibr" rid="CR3">2021</xref>). In actuality, a majority of OS patients present with micrometastases at the time of diagnosis, thereby placing paramount importance on the chemotherapeutic effectiveness for their survival(Gill and Gorlick <xref ref-type="bibr" rid="CR2">2021</xref>; Meltzer and Helman <xref ref-type="bibr" rid="CR3">2021</xref>). Nevertheless, the escalating emergence of chemoresistance has engendered a persistent plateau in the therapeutic effectiveness over successive decades and the adverse effects derived from chemotherapy seriously compromise the physical and psychological well-being of OS patients, necessitating a pressing quest for more efficacious and precise therapeutic alternatives(Gill and Gorlick <xref ref-type="bibr" rid="CR2">2021</xref>; Meltzer and Helman <xref ref-type="bibr" rid="CR3">2021</xref>). Regrettably, targeted therapies have encountered formidable barriers owing to OS intricate genomic intricacies and genetic instability(Wu and Livingston <xref ref-type="bibr" rid="CR4">2020</xref>; Kansara et al. <xref ref-type="bibr" rid="CR5">2014</xref>). Collectively, the limited mechanistic understanding of OS occurrence and metastasis results in the unsatisfactory therapeutic effects, highlighting the importance of profound investigation into OS pathogenesis and progression.</p><p id="Par20">The profound understanding of genetics has highlighted the cancer-therapeutic role of the regulatory mechanism of gene expression(Fresquet et al. <xref ref-type="bibr" rid="CR6">2021</xref>; Tang et al. <xref ref-type="bibr" rid="CR7">2021</xref>). Among the diverse landscape of epigenetic regulations, post-transcriptional modifications, notably RNA modification, have emerged as pivotal players in numerous physiological and pathological statuses(Roundtree et al. <xref ref-type="bibr" rid="CR8">2017</xref>; Zhao et al. <xref ref-type="bibr" rid="CR9">2017</xref>). N7-methylguanosine (m7G) modification, a significant and evolutionarily conserved RNA modification, involves adding a methyl group to the seventh N position of RNA guanine(Merrick and Pavitt <xref ref-type="bibr" rid="CR10">2018</xref>; Luo et al. <xref ref-type="bibr" rid="CR11">2022</xref>; Xia et al. <xref ref-type="bibr" rid="CR12">2023</xref>). Functionally, m7G modification safeguards transcripts from degradation and plays essential roles in transcription elongation, RNA splicing, polyadenylation, nuclear export, and translation(Muthukrishnan et al. <xref ref-type="bibr" rid="CR13">1975</xref>; Shimotohno et al. <xref ref-type="bibr" rid="CR14">1977</xref>; Murthy et al. <xref ref-type="bibr" rid="CR15">1991</xref>; Pei and Shuman <xref ref-type="bibr" rid="CR16">2002</xref>; Konarska et al. <xref ref-type="bibr" rid="CR17">1984</xref>; Lindstrom et al. <xref ref-type="bibr" rid="CR18">2003</xref>; Drummond et al. <xref ref-type="bibr" rid="CR19">1985</xref>; Lewis and Izaurralde <xref ref-type="bibr" rid="CR20">1997</xref>; Furuichi et al. <xref ref-type="bibr" rid="CR21">1977</xref>). The dynamic nature of m7G modification has been correlated with the onset and progression of various diseases, with a particular emphasis on its role in cancer(Luo et al. <xref ref-type="bibr" rid="CR11">2022</xref>; Pandolfini et al. <xref ref-type="bibr" rid="CR22">2019</xref>; Tian et al. <xref ref-type="bibr" rid="CR23">2019</xref>; Arbour et al. <xref ref-type="bibr" rid="CR24">2021</xref>; Stefanska et al. <xref ref-type="bibr" rid="CR25">2014</xref>; Dunn et al. <xref ref-type="bibr" rid="CR26">2019</xref>; Chu and Shatkin <xref ref-type="bibr" rid="CR27">2008</xref>). To date, despite limited research on m7G modification, multiple regulators with m7G methyltransferase activities have been identified, including Methyltransferase 1, TRNA Methylguanosine / WD Repeat Domain 4 (METTL1/WDR4), Williams-Beuren Syndrome Chromosomal Region 22 / TRNA Methyltransferase Activator Subunit 11&#x02009;&#x02212;&#x02009;2 (WBSCR22/TRMT112), RNA Guanine-7 Methyltransferase / RNA Guanine-7 Methyltransferase Activating Subunit (RNMT/RAM)(Luo et al. <xref ref-type="bibr" rid="CR11">2022</xref>; Xia et al. <xref ref-type="bibr" rid="CR12">2023</xref>; Chen et al. <xref ref-type="bibr" rid="CR28">2021</xref>; Alexandrov et al. <xref ref-type="bibr" rid="CR29">2002</xref>), which provides directions for research on m7G modification. At present, researches have revealed dynamic alterations in m7G methylation modification during OS occurrence and development. Wang et al. demonstrated the overexpression of METTL1 and WDR4 were correlated with the unfavorable prognosis of OS patients and their further mechanistic investigations unveiled that the METTL1/WDR4-mediated tRNA m7G modification enhances the proliferative, migratory, and invasive capacities of OS cells, as well as confers resistance to doxorubicin chemotherapy by modulating the translation of oncogenic mRNAs(Wang et al. <xref ref-type="bibr" rid="CR30">2023</xref>). Conversely, He et al. identified METTL1 as a potential tumor suppressor, elucidating its role in promoting OS ferroptosis and reducing chemoresistance through m7G methylation modification of Ferritin Heavy Chain 1 (FTH1) and pri-miR-26a(He et al. <xref ref-type="bibr" rid="CR31">2024</xref>). Therefore, the precise role and associated molecular regulatory mechanisms of m7G methylation modification in the pathogenesis and progression of OS warrant further exploration.</p><p id="Par21">CYFIP1 (Cytoplasmic FMR1 Interacting Protein 1), as the member of the binding complexes of m7G cap, is a gene that encodes proteins regulating cytoskeletal dynamics and protein translation(Rubeis et al. <xref ref-type="bibr" rid="CR32">2013</xref>). Studies have found that CYFIP1 proteins coordinated with ABI1/2, BRK, NCKAP1, WAVE1/2 to form the WAVE regulatory complex (WRC), triggering actin polymerization and formation of membrane ruffles and lamellipodia(Rubeis et al. <xref ref-type="bibr" rid="CR32">2013</xref>; Abekhoukh et al. <xref ref-type="bibr" rid="CR33">2017</xref>; Marino et al. <xref ref-type="bibr" rid="CR34">2015</xref>). Additionally, recent studies have identified CYFIP1 involved in the formation of the CYFIP1-EIF4E-FMR1 complex that binds to the mRNA cap and mediates translational repression(Rubeis et al. <xref ref-type="bibr" rid="CR32">2013</xref>; Marino et al. <xref ref-type="bibr" rid="CR34">2015</xref>; Napoli et al. <xref ref-type="bibr" rid="CR35">2008</xref>). While previous research has primarily focused on the role of CYFIP1 in neuronal development and neurodevelopmental disorders like autism, schizophrenia, and epilepsy(Abekhoukh and Bardoni <xref ref-type="bibr" rid="CR36">2014</xref>; Bonaccorso et al. <xref ref-type="bibr" rid="CR37">2015</xref>), recent evidence highlights its involvement in the carcinogenesis and progression of various cancers(Teng et al. <xref ref-type="bibr" rid="CR38">2016a</xref>, <xref ref-type="bibr" rid="CR39">b</xref>; Chang et al. <xref ref-type="bibr" rid="CR40">2018</xref>; Limaye et al. <xref ref-type="bibr" rid="CR41">2022</xref>; Silva et al. <xref ref-type="bibr" rid="CR42">2009</xref>), suggesting context-specific modulation of CYFIP1 holds promise as a therapeutic approach for cancer treatment. However, the role and regulatory mechanism of CYFIP1 in OS remain poorly understood, limiting its therapeutic potential for this disease.</p><p id="Par22">In this study, we investigated the expression of CYFIP1 in OS tissues, revealing a compelling association between low CYFIP1 expression levels and poorer survival rates among OS patients. Moreover, to gain deeper insights into the functional role of CYFIP1 in OS, we conducted a series of experiments and uncovered its inhibitory effects on the proliferation and migration of OS cells, along with its ability to promote apoptosis. We also uncovered a previously unrecognized interaction between CYFIP1 and RNMT, which together modulate m7G modification of specific target molecules. Notably, we identified Aurora Kinase A Interacting Protein 1 (AURKAIP1) as a downstream target of the CYFIP1-RNMT complexes. This modification led to the increased mRNA stability and enhanced translation of AURKAIP1, a mitochondrial small ribosomal subunit protein, contributing to the perturbation of mitochondrial translation, the upregulation of Ferredoxin 1 (FDX1) protein and eventually triggering cuproptosis in OS cells. In summary, our study has uncovered the existence of the CYFIP1/RNMT/AURKAIP1/FDX1 axis, which represents a potential therapeutic target for OS. These findings significantly advance the field of OS research and have the potential to guide the development of innovative treatment modalities for this complex disease.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Tissue specimens and ethical considerations</title><p id="Par23">Ninety paraffin-embedded OS specimens and paired adjacent normal tissue samples were obtained from patients who underwent tumor resection at the Department of Orthopedics, Xiangya Hospital, Central South University. The patients&#x02019; demographic data, including sex, age, tumor histology, location, diameter, local recurrence, Enneking stage, metastasis, and prognosis, were collected from the hospital&#x02019;s medical record management information system and used for statistical analysis. This study was approved by the Ethics Committee of Xiangya Hospital, Central South University with ethics approval number 2,021,101,013, and informed consent was obtained from the patients or their legal guardians.</p></sec><sec id="Sec4"><title>TCGA data acquisition and processing</title><p id="Par24">The sequencing data and clinical data of 84 OS patients in TARGET-OS cohort were downloaded from The Cancer Genome Atlas Program (TCGA) website (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/ccg/research/genome-sequencing/tcga">https://www.cancer.gov/ccg/research/genome-sequencing/tcga</ext-link>). Patients were separated into high- and low-risk group based on the median mRNA expression and survival curves were generated using the Kaplan&#x02013;Meier method.</p></sec><sec id="Sec5"><title>Cell lines, reagents and transfection</title><p id="Par25">The human osteoblastic cell line hFOB1.19 and OS cell lines MG63 and U2OS were purchased from Pricella Company (Wu Han, China). Under the circumstance of 5% CO<sub>2</sub> and 37&#x000a0;&#x000b0;C, MG63 and U2OS cells were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) (Biological Industries, Israel) while hFOB1.19 cells were maintained in DMEM/F12 medium (Pricella, Wu Han, China). Antibiotics and 10% fetal bovine serum (Gibco, USA) were added in the medium.</p><p id="Par26">These antibodies used in the experiments were as follows: anti-CYFIP1 (ab108220), anti-RNMT (ab254842), anti-E-Cadherin (ab40772), anti-N-Cadherin (ab76011), anti-Caspase3 (ab32351), anti-FDX1 (ab108257), anti-Ki67 (ab15580), anti-CCND1 (ab16663), anti-DYKDDDDK (66008-4-ig, proteintech, China), anti-AURKAIP1 (821937, zenbio, China). Copper chelator, Cuprizone, (370-81-0, MCE) was purchased from MedChemExpress company.</p><p id="Par27">CYFIP1-overexpressed lentivirus and negative control were purchased from Genechem Company (Shanghai, China). siRNAs and shRNAs were synthesized in General Biosystems Company (Nanjing, China). CYFIP1 stably expressed OS cells were infected with the lentivirus and selected with puromycin (1.2&#x000a0;mg/ml) for 4 weeks. Lipofectamine3000 (Invitrogen) was used to transfecte RNAs into tumor cells. The sequences are listed in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p></sec><sec id="Sec6"><title>Immunohistochemistry (IHC) and immunocytochemistry (ICC)</title><p id="Par28">Tissue slides and cell slides were incubated with the corresponding primary and secondary antibodies, details of which were implemented as described in our previous studies(Yuan et al. <xref ref-type="bibr" rid="CR43">2022</xref>).</p></sec><sec id="Sec7"><title>RNA extraction and quantitative polymerase chain reaction (qPCR)</title><p id="Par29">The total RNA was extracted using the AG RNAex Pro RNA extraction kit (AG, Changsha, China) and utilized to synthesize cDNA with the Reverse Transcription kit (AG, Changsha, China). qPCR analysis was carried out on the ABI7500 system using the TBGreen Premix Pro Taq HS Qpcr Kit (AG, Changsha, China). Lastly, we utilized the &#x00394;&#x00394;Cq method to calculate the relative expression levels of each sample and the results were expressed as 2<sup>&#x02212;&#x00394;&#x00394;Cq</sup>. The primer sequences used for all qPCR experiments are listed in Supplementary Table <xref rid="MOESM2" ref-type="media">S2</xref>.</p></sec><sec id="Sec8"><title>Western blotting</title><p id="Par30">Total proteins were extracted from different kinds of cell lysates, separated by 10% SDS polyacrylamide gel electrophoresis, and then transferred onto the polyvinylidene membrane. Incubating in 5% defatted milk, the membranes were incubated overnight with primary antibodies at 4&#x02103; and were then incubated with secondary antibodies for 1&#x000a0;h. Finally, signals of the blots were visualized using an enhanced ECL kit (BL520A, Biosharp, China).</p></sec><sec id="Sec9"><title>Cell proliferation and colony formation</title><p id="Par31">CCK-8 kit (Beyotime, China) and EdU kit (RiboBio, China) were employed to assess cell proliferation. Around 5000 cells/well and 1.2&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells/well were seeded in 96-well plates, respectively. The kits&#x02019; working solutions were added as per the manufacturer&#x02019;s instructions. Cell proliferation was measured using a multifunctional enzyme labeling instrument and fluorescence microscope. For colony formation assay, 1000 cells were seeded in a well of 6-well plates and cultured for 2 weeks.</p></sec><sec id="Sec10"><title>Transwell migration and scratch wound-healing assay</title><p id="Par32">For transwell assay, 3&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells in 200 &#x000b5;L serum-free medium were added to upper chambers (24-well insert, Corning, USA). Bottom chambers contained 800 &#x000b5;L complete medium. After 24&#x000a0;h incubation, cells were fixed in 4% paraformaldehyde and stained with 0.1% crystal violet. Migrating cells in the bottom chamber were counted in five random fields under a microscope after scraping off cells in the upper chamber. In the scratch wound-healing assay, 3&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells were seeded in 6-well plates. When cells reached 90% confluence, a scratch was made using a 1&#x000a0;ml tip head. After 24&#x000a0;h, images were captured using an inverted microscope.</p></sec><sec id="Sec11"><title>Flow cytometry</title><p id="Par33">For cell apoptosis assay, cells were digested with EDTA-free trypsin, washed twice with pre-cooled PBS, and stained using an apoptosis detection kit (#FXP023, 4&#x000a0;A BIOTECH, China). Subsequently, the stained samples were analyzed by flow cytometry after incubation at room temperature in the dark for 10&#x000a0;min.</p><p id="Par34">For reactive oxygen species (ROS) analysis, cells were seeded in 6-well plates and were stained with DHE (US Everbright, Suzhou) diluted with Hank&#x02019;s solution (ratio 1:1000) in an incubator at 37&#x000a0;&#x000b0;C for 20&#x000a0;min. Then, cells were digested with trypsin and washed twice with pre-cooled PBS. Finally, the stained samples were detected by flow cytometry.</p><p id="Par35">For mitochondrial membrane potential (MMP), cells were seeded in 6-well plates and were stained with TMRM (US Everbright, Suzhou) diluted with Hank&#x02019;s solution (ratio 1:2000) in an incubator at 37&#x000a0;&#x000b0;C for 20&#x000a0;min. Then, cells were digested with trypsin and washed twice with pre-cooled PBS. Finally, the stained samples were detected by flow cytometry.</p></sec><sec id="Sec12"><title>RNA stability assay</title><p id="Par36">OS cells were seeded in 6-well plates overnight, and then treated with 5&#x000a0;&#x000b5;g/mL actinomycin D (#S8964, Selleck, USA) at the 0, 3, 6&#x000a0;h. Total RNA was then extracted using TRIzol reagent (AG, Changsha, China) and analyzed by qPCR. Eventually, the linear regression analysis was utilized to estimate the mRNA half-lives time.</p></sec><sec id="Sec13"><title>RNA-sequencing</title><p id="Par37">The total RNA was extracted from CYFIP1 stably expressed U2OS cells and the corresponding control cells using TRIzol reagent (AG, Changsha, China) according to the manufacturer&#x02019;s protocol. The RNA sample quantification, qualification, library preparation, transcriptome sequencing and subsequent analysis were conducted by OE Biotech Co., Ltd. (Shanghai, China). Differential expression analysis was performed using the DESeq2(Love et al. <xref ref-type="bibr" rid="CR44">2014</xref>). Q value&#x02009;&#x0003c;&#x02009;0.05 and foldchange&#x02009;&#x0003e;&#x02009;2 or foldchange&#x02009;&#x0003c;&#x02009;0.5 was set as the threshold for significantly differential expression gene (DEGs).</p></sec><sec id="Sec14"><title>Mass spectrum and CO-IP</title><p id="Par38">Cell lysis was performed using Pierce&#x02122; IP Lysis Buffer (XG351119, Thermo scientific, USA) according to the manufacturer&#x02019;s instructions. Next, the supernatant was extracted by high-speed centrifugation, incubated with 5&#x000a0;&#x000b5;g of specific antibodies against CYFIP1 and rotated with magnetic beads overnight at 4&#x000a0;&#x000b0;C. For mass spectrum, the protein-beads complexes derived from U2OS cell lysis were washed 3 times and proteins were eluted by 20ul glycine-HCL solution. The mass spectrum and subsequent data analysis were constructed by Novogene Corporation (Beijing, China). For CO-IP, protein-beads complexes mixed with loading buffer were incubated in 100&#x02103; 5&#x000a0;min and the supernatant was extracted by high-speed centrifugation for western blotting.</p></sec><sec id="Sec15"><title>RNA immunoprecipitation (RIP)-sequencing or qPCR</title><p id="Par39">RIP was conducted with the RNA immunoprecipitation Kit (BersinBio, Guangzhou, China) according to the manufacturer&#x02019;s instructions. In brief, 5&#x000a0;&#x000b5;g of specific antibodies against rabbit immunoglobulin G, CYFIP1 or RNMT were incubated with prepared CYFIP1 stably expressed U2OS cells and the corresponding control cells lysates overnight at 4&#x000a0;&#x000b0;C and rotated with magnetic beads 1&#x000a0;h at the second day. Subsequently, the RNA-protein-beads complexes were washed 5 times and eluted by elution fluid mixed with proteinase K. Finally, phenol-chloroform-isopentanol mixture was utilized for RNA extraction. The sequencing library and subsequent data analysis were constructed by Novogene Corporation (Beijing, China). The relative interaction between CYFIP1-RNMT complexes and their targeted transcripts were validated by qPCR and normalized to the input.</p></sec><sec id="Sec16"><title>m7G meRIP-sequencing or qPCR</title><p id="Par40">MeRIP experiment and high through-put sequencing and data analysis were conducted by Seqhealth Technology Co., LTD (Wuhan, China). Total RNAs were extracted from CYFIP1 stably expressed U2OS cells and the corresponding control cells and then undergone DNA digestion, quality testing, quantification. 50&#x000a0;&#x000b5;g total RNAs were used for polyadenylated RNA enrichment by VAHTS mRNA Capture Beads (VAHTS, cat. NO. N401-01/02). 20mM ZnCl2 was added to mRNA and incubated at 95&#x02103; for 5&#x02013;10&#x000a0;min until the RNA fragments were mainly distributed in 100-200nt. Then 10% RNA fragments was saved as &#x0201c;Input&#x0201d; and the rest was used for m7G immunoprecipitation. The specific anti-m7G antibody (#RN017M, MBL) was applied for m7G immunoprecipitation. RNA samples of both input and IP were prepared using TRIzol reagent (Invitrogen, cat. NO 15596026). After the stranded RNA sequencing using Illumina<sup>&#x000ae;</sup> platform, raw sequencing data undergone quality control, mapping, peak annotation, and subsequent data analysis. The m7G-modified transcripts were validated by qPCR and normalized to the input.</p></sec><sec id="Sec17"><title>Mitochondrial proteomics</title><p id="Par41">Mitochondrion were extracted using the mitochondrial extraction kit (SM0020, Solarbio, Beijing). Subsequently, mitochondrial proteins were extracted from cell lysates, quantified using BCA method, and separated by 12% SDS polyacrylamide gel electrophoresis. Then, the obtained proteins were undergone enzymolysis, label, enrichment, and Mass spectrometry analysis. Spectronaut (Version 15.3.210906.50606) was used to search all of the raw data thoroughly against the sample protein database. Database search was performed with Trypsin digestion specificity. Alkylation on cysteine was considered as fixed modifications in the database searching. Protein, peptide and PSM&#x02019;s false discovery rate (FDR) all set to 0.01. For DIA data, the quantification FDR also set to 0.05. Quantity MS-level was set at MS2. The mass spectrum and subsequent data analysis were conducted by OE Biotech Co., Ltd. (Shanghai, China).</p></sec><sec id="Sec18"><title>Xenograft mouse models</title><p id="Par42">The animal experiments in this study obtained approval from the Animal Care and Ethics Committee of Xiangya Hospital of Central South University (Changsha, China). The tumor in mice did not exceed 20 cubic mm and any dimension was less than 20&#x000a0;mm in diameter, which met the animal ethical standards of Xiangya Hospital. In brief, four- to six-week-old female nude mice were divided into two group containing six mice, of which one group was injected CYFIP1 stably expressed U2OS cells while other group was injected control U2OS cells. Subsequently, the tumor volume of mice was measured every 5 days, and tumors were harvested after 20 days, with their weights measured.</p></sec><sec id="Sec19"><title>Statistical analysis</title><p id="Par43">GraphPad Prism 8 were used for data processing and statistical analysis of all the experimental results. The quantitative data were expressed as the mean&#x02009;&#x000b1;&#x02009;SD and tested by student&#x02019;s t-test was while the qualitative data expressed in frequency were analyzed by Chi-square test or Fisher&#x02019;s exact test. The indicated P value (* <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) was considered statistically significant.</p><p id="Par44">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Correlation of CYFIP1 expression with clinicopathological features of OS patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Clinicopathological parameter</th><th align="left" colspan="2">CYFIP1 protein expression</th><th align="left" rowspan="2"><italic>P</italic> value</th></tr><tr><th align="left">Low (<italic>n</italic>&#x02009;=&#x02009;48)</th><th align="left">High (<italic>n</italic>&#x02009;=&#x02009;42)</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left"/><td align="left"/><td char="." align="char">0.9999</td></tr><tr><td align="left">&#x02003;&#x0003c;&#x02009;21</td><td char="." align="char">40</td><td char="." align="char">35</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x02265;&#x02009;21</td><td char="." align="char">8</td><td char="." align="char">7</td><td align="left"/></tr><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td char="." align="char">0.9757</td></tr><tr><td align="left">&#x02003;Female</td><td char="." align="char">15</td><td char="." align="char">13</td><td align="left"/></tr><tr><td align="left">&#x02003;Male</td><td char="." align="char">33</td><td char="." align="char">29</td><td align="left"/></tr><tr><td align="left">Tumour size (cm)</td><td align="left"/><td align="left"/><td char="." align="char">0.0001</td></tr><tr><td align="left">&#x02003;&#x0003c;&#x02009;8</td><td char="." align="char">16</td><td char="." align="char">31</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x02265;&#x02009;8</td><td char="." align="char">32</td><td char="." align="char">11</td><td align="left"/></tr><tr><td align="left">Local recurrence</td><td align="left"/><td align="left"/><td char="." align="char">0.1981</td></tr><tr><td align="left">&#x02003;Yes</td><td char="." align="char">6</td><td char="." align="char">2</td><td align="left"/></tr><tr><td align="left">&#x02003;No</td><td char="." align="char">42</td><td char="." align="char">40</td><td align="left"/></tr><tr><td align="left">Enneking&#x02019;s stage</td><td align="left"/><td align="left"/><td char="." align="char">&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">&#x02003;IIA</td><td char="." align="char">8</td><td char="." align="char">5</td><td align="left"/></tr><tr><td align="left">&#x02003;IIB</td><td char="." align="char">20</td><td char="." align="char">33</td><td align="left"/></tr><tr><td align="left">&#x02003;III</td><td char="." align="char">22</td><td char="." align="char">2</td><td align="left"/></tr><tr><td align="left">Anatomic location</td><td align="left"/><td align="left"/><td char="." align="char">0.1163</td></tr><tr><td align="left">&#x02003;Femur</td><td char="." align="char">24</td><td char="." align="char">18</td><td align="left"/></tr><tr><td align="left">&#x02003;Tibia</td><td char="." align="char">8</td><td char="." align="char">16</td><td align="left"/></tr><tr><td align="left">&#x02003;Humerus</td><td char="." align="char">11</td><td char="." align="char">6</td><td align="left"/></tr><tr><td align="left">&#x02003;Others</td><td char="." align="char">5</td><td char="." align="char">2</td><td align="left"/></tr><tr><td align="left">Lung metastasis</td><td align="left"/><td align="left"/><td char="." align="char">0.0072</td></tr><tr><td align="left">&#x02003;Yes</td><td char="." align="char">22</td><td char="." align="char">8</td><td align="left"/></tr><tr><td align="left">&#x02003;No</td><td char="." align="char">26</td><td char="." align="char">34</td><td align="left"/></tr><tr><td align="left">Histology</td><td align="left"/><td align="left"/><td char="." align="char">0.2357</td></tr><tr><td align="left">&#x02003;Conventional osteosarcoma</td><td char="." align="char">35</td><td char="." align="char">35</td><td align="left"/></tr><tr><td align="left">&#x02003;Others</td><td char="." align="char">13</td><td char="." align="char">7</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Differences between groups were done by the Chi-square test</p></table-wrap-foot></table-wrap>
</p><p id="Par45">
<fig id="Fig1"><label>Fig. 1</label><caption><p>CYFIP1 expression in osteosarcoma and its relationship to patient survival. <bold>A</bold>,<bold> B</bold>. Low CYFIP1 expression was detected in OS tissues while high CYFIP1 expression in their adjacent tissues. <bold>C</bold>. IHC staining showed the representative images of low or high expression of CYFIP1. <bold>D</bold>. Kaplan-Meier survival curve exhibited that low CYFIP1 expression was associated with the worse survival statuses in Xiangya hospital (Log-rank <italic>p</italic>&#x02009;=&#x02009;0.0011, HR&#x02009;=&#x02009;0.377, n[high]&#x02009;=&#x02009;42, n[low]&#x02009;=&#x02009;48 ). <bold>E</bold>. Kaplan-Meier survival curve exhibited that low CYFIP1 expression was associated with the worse survival statuses in TARGET-OS cohort (Log-rank <italic>p</italic>&#x02009;=&#x02009;0.0006, HR&#x02009;=&#x02009;0.261, <italic>n</italic>&#x02009;=&#x02009;42 per group). The data represent the mean&#x02009;&#x000b1;&#x02009;S.D. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 or **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 indicates a significant difference between the indicated groups</p></caption><graphic xlink:href="10020_2025_1127_Fig1_HTML" id="d33e891"/></fig>
</p><p id="Par46">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Overexpression of CYFIP1 inhibited the proliferation and metastasis while promoted the apoptosis of osteosarcoma cells in vitro. <bold>A</bold>,<bold> B</bold>. WB and qPCR exhibited the low expression of CYFIP1 in OS cells. <bold>C-F</bold>. WB and qPCR exhibited the overexpression efficiency of lentivirus transfection. <bold>G</bold>. Overexpression of CYFIP1 facilitated osteosarcoma cells apoptosis. <bold>H-K</bold>. CCK8. EdU and colony formation assays exhibited overexpression of CYFIP1 inhibited osteosarcoma cells proliferation. <bold>L</bold>,<bold> M</bold>. Overexpression of CYFIP1 inhibited osteosarcoma cells migration. The data represent the mean&#x02009;&#x000b1;&#x02009;S.D. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 indicates a significant difference between the indicated groups</p></caption><graphic xlink:href="10020_2025_1127_Fig2_HTML" id="d33e936"/></fig>
</p></sec></sec><sec id="Sec20"><title>Results</title><sec id="Sec21"><title>Low expression of CYFIP1 was detected in OS tissues and associated with the worse survival rate</title><p id="Par47">Previous studies have implicated dysregulated CYFIP1 expression in certain cancers, particularly with regards to disease progression, including invasion and metastasis(Silva et al. <xref ref-type="bibr" rid="CR42">2009</xref>). In our investigation, to explore the expression landscape of CYFIP1 in OS, IHC and WB assays were employed. As expected, diminished CYFIP1 expression was detected in OS tissues compared to corresponding adjacent normal tissue (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A.B). The detailed clinicopathological features of OS patients were shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Further, to elucidate the association between CYFIP1 expression and overall survival rates in OS patients, we stratified them into high-expressing (<italic>n</italic>&#x02009;=&#x02009;42) and low-expressing (<italic>n</italic>&#x02009;=&#x02009;48) groups based on IHC staining results (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C), and Kaplan-Meier analysis demonstrated a significant negative correlation between CYFIP1 expression and OS patients&#x02019; overall survival rate (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). Similarly, the negative correlation was further validated in the TARGET-OS cohort through sequencing and follow-up data (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E). Given the differential expression of CYFIP1 between OS tissues and their corresponding adjacent normal tissues, we dedicated to explore its effect and underlying mechanism during OS pathogenesis and progression.</p><p id="Par48">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Validation of the role of CYFIP1 via downregulation experiment. <bold>A-D</bold>. WB and qPCR exhibited the knockdown efficiency of shRNA transfection. <bold>E-F</bold>. Knockdown of CYFIP1 promoted osteosarcoma cells migration. <bold>G</bold>. Knockdown of CYFIP1 decreased osteosarcoma cells apoptosis. <bold>H-J</bold>. CCK8 and EdU assays exhibited knockdown of CYFIP1 promoted osteosarcoma cells proliferation. The data represent the mean&#x02009;&#x000b1;&#x02009;S.D. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 indicates a significant difference between the indicated groups</p></caption><graphic xlink:href="10020_2025_1127_Fig3_HTML" id="d33e1003"/></fig>
</p><p id="Par49">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Validation of the role of CYFIP1 via in-vivo experiment. <bold>A-C</bold>. Overexpression of CYFIP1 inhibited osteosarcoma proliferation in vivo. <bold>D</bold>. Overexpression of CYFIP1 elevated the expression of E-cadhesion and caspase-3 while decreased the expression of Ki67 and N-cadhesion. The data represent the mean&#x02009;&#x000b1;&#x02009;S.D. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 indicates a significant difference between the indicated groups</p></caption><graphic xlink:href="10020_2025_1127_Fig4_HTML" id="d33e1033"/></fig>
</p></sec><sec id="Sec22"><title>Over-expression of CYFIP1 suppressed the proliferation and migration and facilitated the apoptosis of OS cells</title><p id="Par50">To validate CYFIP1 expression at the cytological level, we analyzed CYFIP1 proteins and RNAs extracted from OS cells and osteoblasts. The results revealed a downregulation of both CYFIP1 mRNAs and proteins in OS cells, which was consistent with our histological experiment (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A.B). Subsequently, we sought to investigate the impact of CYFIP1 on the biological behavior of OS cells by enhancing CYFIP1 expression through lentivirus transfection (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C-F). Following the upregulation of CYFIP1 expression, we observed a decrease in cell viability through colony formation, CCK8, and EdU assays, along with a substantial increase in OS cell apoptosis (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>G-K). Considering previous studies indicating CYFIP1 as a suppressor of invasion in various cancers, we also explored its role in OS metastasis and found that overexpression of CYFIP1 significantly inhibited the migration of OS cells, which corroborated earlier findings (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>L.M). To further investigate the impact of CYFIP1, we employed siRNA to knock down CYFIP1 expression and confirmed its downregulation using WB and qPCR (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A-D). Consistent with the findings from CYFIP1 overexpression, the downregulation of CYFIP1 promoted the proliferation and migration of OS cells while reducing apoptosis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>E-J). Moreover, we investigated molecules associated with apoptosis, cell cycles, and metastasis to further validate our findings. As expected, Cleaved Caspase-3 and E-cadherin were upregulated, while CCND1 and N-cadherin exhibited opposing trends (supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>A.B). Therefore, CYFIP1 exhibited an excellent anti-OS effect in term of the in-vitro experiment, triggering our interesting to further exploration.</p><p id="Par51">
<fig id="Fig5"><label>Fig. 5</label><caption><p>RNMT serves as a partner of CYFIP1. <bold>A-D</bold>. The interacted genes of CYFIP1 in mass spectrum and the corresponding functional enrichment. <bold>E.</bold> PPI from String website. <bold>F-G</bold>. ICC exhibit the localization of CYFIP1 and RNMT in osteosarcoma cells and coIP proved the interaction between CYFIP1 and RNMT</p></caption><graphic xlink:href="10020_2025_1127_Fig5_HTML" id="d33e1079"/></fig>
</p><p id="Par52">
<fig id="Fig6"><label>Fig. 6</label><caption><p>CYFIP1 coordinated with RNMT to facilitate the m7G modification of their targets. <bold>A</bold>,<bold> B</bold>. RIP and m7G-RIP sequencing. <bold>C</bold>. The intersected genes between mRNA, RIP and m7G-RIP sequencing. <bold>D-I</bold>. RIP- and m7G-RIP-qPCR identified AURKAIP1, PYRC1 and TK1 as the targets of CYFIP1-RNMT complexes. <bold>J</bold>,<bold> K</bold>. Gene set enrichment analysis of mRNA sequencing. <bold>L</bold>,<bold> M</bold>. The RNA stability assays of AURKAIP1. <bold>N</bold>. Overexpression of CYFIP1 increased the expression of AURKAIP1. The data represent the mean&#x02009;&#x000b1;&#x02009;S.D. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, and ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 indicates a significant difference between the indicated groups</p></caption><graphic xlink:href="10020_2025_1127_Fig6_HTML" id="d33e1128"/></fig>
</p></sec><sec id="Sec23"><title>Overexpression of CYFIP1 suppressed human OS growth in vivo</title><p id="Par53">To further investigate the tumorigenicity of CYFIP1 in vivo, we subcutaneously injected U2OS cells expressing different levels of CYFIP1 into nude mice. As anticipated, the growth of tumors derived from CYFIP1-stably-expressed OS cells was notably suppressed compared to NC group (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). On day 20 post-injection, the tumors were surgically excised, and their weights were measured, demonstrating the significant anti-OS effect of CYFIP1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B.C). Additionally, IHC staining was performed on the tumor samples, confirming the overexpression of CYFIP1 in the CYFIP1-stably-expressed OS cells. Furthermore, compared to the NC groups, the expression of Caspase3 and E-cadherin increased, while Ki67 and N-cadherin decreased in the CYFIP1-stably-expressed groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D). Overall, our in vivo assays align with the observations made in vitro, providing further evidence for the tumor-suppressing role of CYFIP1.</p><p id="Par54">
<fig id="Fig7"><label>Fig. 7</label><caption><p>CYFIP1 coordinated with RNMT to induce cuproptosis via AURKAIP1/FDX1 pathway. <bold>A</bold>,<bold> B</bold>. Gene set enrichment analysis and volcano map of mitochondrial proteomics. <bold>C</bold>,<bold> D</bold>. Overexpression of CYFIP1 increased the expression of AURKAIP1 and FDX1. <bold>E</bold>. Overexpression of CYFIP1 decreased the mitochondrial membrane potential in osteosarcoma cells. <bold>F</bold>. Overexpression of CYFIP1 elevated the ROS level in osteosarcoma cells. <bold>G</bold>. Overexpression of CYFIP1 destroyed the structure of mitochondrion. <bold>H</bold>. The overexpression of CYFIP1 could induce the aggregation of DLAT</p></caption><graphic xlink:href="10020_2025_1127_Fig7_HTML" id="d33e1177"/></fig>
</p><p id="Par55">
<fig id="Fig8"><label>Fig. 8</label><caption><p>AURKAIP1 knockdown and copper chelator reversed the anti-osteosarcoma effects derived from CYFIP1 overexpression. <bold>A</bold>. WB exhibited the knockdown efficiency of siRNA transfection. <bold>B</bold>. EdU assays exhibited knockdown of AURKAIP1 rescued osteosarcoma cells proliferative ability. <bold>C</bold>. Knockdown of AURKAIP1 rescued osteosarcoma cells apoptosis. <bold>D</bold>. Knockdown of AURKAIP1 promoted osteosarcoma cells migration. <bold>E</bold>,<bold> F</bold>. Knockdown of AURKAIP1 decreased ROS level and elevated MMP. <bold>G</bold>. Application of copper chelator rescued osteosarcoma cells apoptosis. <bold>H</bold>. Application of copper chelator promoted osteosarcoma cells migration. <bold>I</bold>,<bold> J</bold>. Application of copper chelator decreased ROS level and elevated MMP. <bold>K</bold>. The diagram of anti-OS effects of CYFIP1. The data represent the mean&#x02009;&#x000b1;&#x02009;S.D. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, and ****<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001 indicates a significant difference between the indicated groups</p></caption><graphic xlink:href="10020_2025_1127_Fig8_HTML" id="d33e1235"/></fig>
</p></sec><sec id="Sec24"><title>RNMT served as a partner of CYFIP1</title><p id="Par56">To investigate the underlying mechanism of CYFIP1-mediated suppression of OS growth and metastasis, we conducted an in-depth analysis using a combination of molecular techniques and bioinformatics tools. Our study employed mRNA sequencing between CYFIP1 stably expressed groups and NC groups, and identified a total of 4954 DEGs, in which 1386 were found to be down-regulated and 3568 showed up-regulation (supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>A). Subsequently, we performed comprehensive Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to gain insights into the functional implications of these DEGs. The GO analysis revealed a significant enrichment of DEGs in cytoplasmic translation-related pathways, particularly mitochondrial translation-related processes. Specifically, these pathways included translation, SRP-dependent cotranslational protein targeting to the membrane, mitochondrial translational elongation, mitochondrial translational termination, and structural constituents of ribosomes (supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>B). This suggests a potential involvement of CYFIP1 in translation processes and mitochondrial metabolism. In the KEGG analysis, we observed a prominent enrichment of DEGs in pathways such as ribosome, ubiquitin-mediated proteolysis, signaling pathways regulating pluripotency of stem cells, and colorectal cancer (supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>C). These findings suggest that CYFIP1 may play a regulatory role in translation-related pathways that are implicated in the pathogenesis and progression of tumors.</p><p id="Par57">To further explore the interacting partners of CYFIP1, we employed mass spectrometry to identify proteins that interact with CYFIP1. Our analysis identified a set of 214 CYFIP1-interacting proteins, with a predominant representation of cytoplasmic proteins (supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>D). Functional enrichment analysis of these genes using GO, KEGG, Clusters of Orthologous Groups of proteins (COGs), and InterPro (IPR) indicated a strong focus on translation-related pathways, posttranslational modification, and the RNA recognition motif domain (supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>E-I). To gain more insight into the specific interactions involving CYFIP1, we intersected the DEGs with the genes corresponding to CYFIP1-interacting proteins and identified 51 genes of interest (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A). Then, functional enrichment was performed for these 51 genes and indicated the translation-related pathways and RNA modification were enriched (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B.C). Meantime, gene set enrichment analysis (GSEA) exhibited the translation-related pathways, particularly cytoplasmic translation, were enriched in NC groups (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>D). Subsequently, we constructed a protein-protein interaction (PPI) network using the STRING website and identified four genes&#x02014;NCKAP1, ABI2, NCL, and RNMT&#x02014;that exhibited significant associations with CYFIP1 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>E). Previous studies indicated RNMT, a RNA guanine-7 methyltransferase, could take part in mRNA cap methylation and the methylation of cytoplasmically recapped RNAs, thereby influencing transcription and translation processes(Xiao et al. <xref ref-type="bibr" rid="CR45">2023</xref>). Considering the prevalence of translation-related pathways in the GSEA results of our transcriptome data and the co-expression relationship between CYFIP1 and RNMT in the PPI network, we hypothesize that CYFIP1 may interact with RNMT to modulate the expression and fate of specific genes. To validate the interaction between CYFIP1 and RNMT, we conducted ICC and CO-IP experiments. Consistent with our expectations, ICC analysis demonstrated that CYFIP1 primarily localizes to the cytoplasm, while RNMT exhibits both nuclear and cytoplasmic localization patterns (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>F). Furthermore, CO-IP experiments confirmed the physical interaction between CYFIP1 and RNMT (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>G). These findings strongly support the notion that RNMT may act as a functional partner of CYFIP1, contributing to its regulatory activities and biological functions.</p></sec><sec id="Sec25"><title>CYFIP1 coordinated with RNMT to m7G modify their targets and regulate their expression</title><p id="Par58">Considering the identification of RNMT as an RNA guanine-7 methyltransferase, we hypothesized that CYFIP1-RNMT complexes could potentially influence the m7G modification of specific genes. To investigate this hypothesis, we performed RIP-sequencing and m7G-RIP-sequencing to identify the target genes. The results revealed 215 differential peaks in m7G-RIP-sequencing and 1872 differential peaks in RIP-sequencing (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A-C). After annotating these peaks, we intersected them with the DEGs identified in mRNA sequencing, resulting in the identification of nine genes that were present in all three datasets: CHD8, UBR4, NCEH1, TK1, GPRC5C, AURKAIP1, C16orf72, PYCR1, and GPANK1 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C). To validate the sequencing results and eliminate false positives, we conducted RIP-qPCR and m7G-RIP-qPCR experiments, ultimately confirming three valid genes: AURKAIP1, TK1, and PYRC1 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>D-I).Interestingly, GSEA of our transcriptome sequencing data revealed significant enrichment of mitochondrial metabolism-related pathways, such as mitochondrial translation elongation and mitochondrial translation termination, in the NC group (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>J.K). This finding suggests that the regulation of mitochondrial metabolism-related pathways may play a crucial role in the tumor-suppressing effect of CYFIP1. Additionally, we found that AURKAIP1, the most significant gene identified in the m7G-RIP-sequencing, is involved in mitochondrial translation-related pathways, leading us to select AURKAIP1 for further investigation (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>D.G). To validate the impact of m7G modification on the expression of AURKAIP1, we conducted an RNA stability experiment and observed that overexpression of CYFIP1 significantly extended the half-life of AURKAIP1 mRNA (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>L.M). Furthermore, through Western blot assay, we discovered that overexpression of CYFIP1 increased the expression of AURKAIP1 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>N). Eventually, to validate the m7G modification of AURKAIP1 was derived from RNMT during CYFIP1 overexpression, we knocked down the RNMT expression and performed Western blot, RIP-qPCR and m7G-RIP-qPCR assays and found that the knock-down of RNMT indeed decreased the m7G modification and expression of AURKAIP1, supporting CYFIP1 could coordinate with RNMT to m7G modifies AURKAIP1 and regulate its expression (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>A-C). Therefore, it can be concluded that CYFIP1 coordinate with RNMT to enhance the stability of AURKAIP1 mRNA through m7G modification, thereby facilitating the expression of AURKAIP1.</p></sec><sec id="Sec26"><title>CYFIP1 interacted with RNMT to induce OS cuproptosis via AURKAIP1/FDX1 pathway</title><p id="Par59">Given the mitochondrial translation-related role of AURKAIP1 and the enrichment of mitochondrial translation-related pathways in our bioinformatics data, we performed mitochondrial proteomics to explore the downstream of AURKAIP1. Interesting, different from mRNA sequencing, mitochondrial proteomics indicated that mitochondrial translation was enriched in CYFIP1 overexpressed group (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A).</p><p id="Par60">Notably, FDX1, the core member of cuproptosis, were upregulated in the CYFIP1 overexpressed group in mitochondrial proteomics (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>B). Subsequently, to confirm the results of mitochondrial proteomics, we utilized WB blotting and found that after the overexpression of CYFIP1, both AURKAIP1 and FDX1 were upregulated (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C). Meantime, the corresponding IHC staining slides derived from our xenograft mouse models shown that the overexpression of CYFIP1 was followed with the significant upregulation of AURKAIP1 and FDX1 (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>D). Since FDX1 was proved to result in cuproptosis and the subsequent mitochondrial dysregulation, we detected the change of MMP and ROS level after the overexpression of CYFIP1. As expected, the overexpression of CYFIP1 triggered MMP decline increased ROS level (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>E.F). Meantime, through transmission electron microscope (TEM), we found the structure of mitochondrion became disorganized after the overexpression of CYFIP1 (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>G). Since cuproptosis involves the aggregation of lipoylated proteins, we tested the aggregation of DLAT, a kind of lipoylated proteins of Tricarboxylic acid (TCA) cycle and the results of WB suggested that the overexpression of CYFIP1 could induce the aggregation of DLAT, further confirming the occurrence of OS cells cuproptosis (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>H).</p><p id="Par61">To further confirmed the anti-OS effects of CYFIP1 were derived from the overexpression of AURKAIP1, we knockdown AURKAIP1 via siRNA (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>A). Indeed, AURKAIP1 knockdown partially reversed the anti-OS effects associated with CYFIP1 overexpression. After AURKAIP1 knockdown, FCM apoptosis assay shown that the apoptosis rate of OS cells significantly reduced while transwell and EdU assays found that OS cells migration ability was restored. (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>B-D). Meantime, flow cytometry assays also exhibited that the ROS level was decreased and MMP was elevated when AURKAIP1 was knockdown (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>E.F). Eventually, to validated whether the anti-OS effects of CYFIP1 could be attribute to cuproptosis, we utilized copper chelator to reverse the anti-OS effects of CYFIP1 and found that copper chelator could rescue OS cells apoptosis resulted from CYFIP1 overexpression (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>G). In the meantime, the application of copper chelator also partially counteract the inhibition derived from CYFIP1 overexpression on OS cells migration (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>H). Additionally, after the application of copper chelator, elevating ROS levels were weaken and MMP exhibited a downward trend, compared with DMSO group (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>I-J). These experimental results confirm that CYFIP1 interacts with RNMT to induce OS cuproptosis via the AURKAIP1/FDX1 pathway (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>K).</p></sec></sec><sec id="Sec27"><title>Discussion</title><p id="Par62">The advancement of treatments, particularly the introduction of multi-drug chemotherapies, has significantly extended the survival of OS patients(Gill and Gorlick <xref ref-type="bibr" rid="CR2">2021</xref>; Meltzer and Helman <xref ref-type="bibr" rid="CR3">2021</xref>). However, the survival rate for patients with metastatic and recurrent OS remains dismal(Ritter et al. <xref ref-type="bibr" rid="CR1">2010</xref>). Furthermore, the increasing development of chemotherapy resistance poses a challenge to improving the survival rate of OS patients(Meltzer and Helman <xref ref-type="bibr" rid="CR3">2021</xref>). Therefore, elucidating the underlying mechanisms of OS oncogenesis and progression is crucial for early diagnosis, precise treatment, and prognosis improvement. Recent studies have highlighted the therapeutic significance of epigenetics, in which m7G modification has garnered increasing attention due to substantial evidence indicating its impact on tumor pathogenesis and progression(Rong et al. <xref ref-type="bibr" rid="CR46">2021</xref>; Barbieri and Kouzarides <xref ref-type="bibr" rid="CR47">2020</xref>; Han et al. <xref ref-type="bibr" rid="CR48">2022</xref>, <xref ref-type="bibr" rid="CR50">2023</xref>; Bahr et al. <xref ref-type="bibr" rid="CR49">1999</xref>; Orellana et al. <xref ref-type="bibr" rid="CR51">2021</xref>). To date, m7G modification was proved to involve in the proliferation, migration, drug-resistance, apoptosis, and autophagy in certain cancers, such as lung, bladder, colon, pancreatic cancer and intrahepatic, esophageal squamous cell carcinoma(Luo et al. <xref ref-type="bibr" rid="CR11">2022</xref>; Xia et al. <xref ref-type="bibr" rid="CR12">2023</xref>; Pandolfini et al. <xref ref-type="bibr" rid="CR22">2019</xref>; Ma et al. <xref ref-type="bibr" rid="CR52">2021</xref>; Dai et al. <xref ref-type="bibr" rid="CR53">2021</xref>; Song et al. <xref ref-type="bibr" rid="CR54">2020</xref>). Therefore, understanding the effects and mechanisms of m7G modification contributes to the study of oncogenesis and progression in these cancers, providing novel insights into cancer treatments. Though studies conducted by Wang et al. revealed the importance of m7G modification in OS oncogenesis and progression, the function of m7G mRNA modification and its underlying mechanism in OS remain largely limited. In the present study, we first revealed the role and underlying mechanism of m7G modification derived from CYFIP1 and the tumor-suppressing role of CYFIP1 against OS. Mechanistically, we discovered that CYFIP1 could coordinate with RNMT to influence the m7G modification and facilitate the translational efficiency of AURKAIP1 mRNA, which lead to the upregulation of FDX1 and the subsequent OS cuproptosis, providing the researchers and clinicians with novel insight into OS researches and treatments.</p><p id="Par63">In this study, through validated 90 OS patients in Xiangya hospital, we initially observed differential expression of CYFIP1 between normal tissues and OS tissues. Further exploration revealed a negative correlation between the expression of CYFIP1 and the prognosis of OS patients. Considering the differential expression and prognostic significance of CYFIP1, its role and mechanism may be crucial in the pathogenesis and development of OS. Previous research has shown that CYFIP1 can form binding complexes with eIF4E and FMR1 to interact with the m7G cap of mRNA, exerting a translation-suppressing effect(Rubeis et al. <xref ref-type="bibr" rid="CR32">2013</xref>; Bramham et al. <xref ref-type="bibr" rid="CR55">2016</xref>). Moreover, several recent studies have demonstrated the antitumor effects of CYFIP1 in various cancers(Chang et al. <xref ref-type="bibr" rid="CR40">2018</xref>; Silva et al. <xref ref-type="bibr" rid="CR42">2009</xref>; Dziunycz et al. <xref ref-type="bibr" rid="CR56">2017</xref>). However, it remains to be determined whether the effect of CYFIP1 on translation plays an anti-OS role. In our studies, we observed significant antitumor effects of CYFIP1, and mass spectrometry analysis indicated an interaction between CYFIP1 and RNMT. Earlier studies have identified RNMT as an RNA guanine-7 methyltransferase, primarily expressed in the nucleus and involved in mRNA cap methylation(Dunn et al. <xref ref-type="bibr" rid="CR26">2019</xref>; Aregger et al. <xref ref-type="bibr" rid="CR57">2016</xref>; Osborne et al. <xref ref-type="bibr" rid="CR58">2022</xref>). More recently, Trotman et al. discovered that RNMT is not only expressed in the nucleus but also in the cytoplasm, participating in the methylation of cytoplasmically recapped RNAs and regulating the translation of specific genes(Trotman et al. <xref ref-type="bibr" rid="CR59">2017</xref>). Additionally, Osborne et al. found that RNMT can compete for the binding of well-established eIF4E-binding proteins (4E-BPs) and form m7G cap-eIF4E-RNMT trimeric complexes, facilitating eIF4E to capture newly capped RNA(Osborne et al. <xref ref-type="bibr" rid="CR58">2022</xref>). Considering that CYFIP1 has been identified as a 4E-BP(Napoli et al. <xref ref-type="bibr" rid="CR35">2008</xref>), we further explored whether CYFIP1 interacts with RNMT to influence the translation of specific RNAs. Consistent with the findings of Trotman et al., our ICC analysis demonstrated the presence of RNMT in both the nucleus and cytoplasm, offering the possibility of interaction with CYFIP1, a cytoplasmic protein. Furthermore, co-IP further confirmed the interaction between CYFIP1 and RNMT. Collectively, considering that RNMT acts as an RNA guanine-7 methyltransferase, CYFIP1 may form complexes with RNMT to influence m7G modification in OS cells. As expected, the combination of m7G-RIP, RIP, and RNA stability assays confirmed that CYFIP1-RNMT complexes can m7G modify and stabilize AURKAIP1 mRNA, facilitating its translation. AURKAIP1, which is located in the mitochondrion and nucleoplasm, has been found to play a role in the positive regulation of proteolysis and is involved in mitochondrial translation and protein metabolism(Key et al. <xref ref-type="bibr" rid="CR60">2022</xref>; Koc et al. <xref ref-type="bibr" rid="CR61">2013</xref>).</p><p id="Par64">Intriguingly, our transcriptome analysis revealed that besides translation-related pathways, there was also enrichment of mitochondrion translation-related pathways, indicating that changes in CYFIP1 expression might be associated with alterations in mitochondrial translation. To illuminate the effects derived from AURKAIP1, we performed the mitochondrial proteomics and found the upregulation of FDX1. Since cuproptosis was referred by Tsvetkov et al., cuproptosis-related genes, such as FDX1, gained enormous interest and were regarded as the emerging anticancer hotspots(Tsvetkov et al. <xref ref-type="bibr" rid="CR62">2022</xref>). Considering FDX1 serves as the core status of cuproptosis, we hypothesized that anti-OS effects of CYFIP1 may be associated with cuproptosis. Subsequently, our experimental results confirm that CYFIP1 overexpression resulted in MMP decline and elevated ROS level, leading to damaged mitochondrial structure and the eventual OS cuproptosis. Eventually, we knock downed AURKAIP1 and utilized copper chelator to recuse the anti-OS effects derived from CYFIP1 overexpression and found AURKAIP1 knockdown and copper chelator could reverse the pro-apoptosis, elevating ROS level, and MMP decline resulted from CYFIP1 overexpression. Taken altogether, CYFIP1 could coordinate with RNMT to trigger OS cuproptosis through m7G modifying AURKAIP1 mRNA. Previous studies highlighted CYFIP1 served as the member of WRC complexes and CYFIP1-EIF4E-FMR1 complexes, broadly involving in the cytoskeletal dynamics and protein translation of various cancers(Rubeis et al. <xref ref-type="bibr" rid="CR32">2013</xref>; Marino et al. <xref ref-type="bibr" rid="CR34">2015</xref>; Teng et al. <xref ref-type="bibr" rid="CR38">2016a</xref>, <xref ref-type="bibr" rid="CR39">b</xref>; Silva et al. <xref ref-type="bibr" rid="CR42">2009</xref>). Here, we revealed the role of CYFIP1 during m7G modification and cuproptosis, providing new perspective into the role and mechanism of CYFIP1.</p><p id="Par65">Since the genome complexity and instability of OS have baffled the targeted therapies, OS treatments fail to achieve revolutionary progresses(Wu and Livingston <xref ref-type="bibr" rid="CR4">2020</xref>; Kansara et al. <xref ref-type="bibr" rid="CR5">2014</xref>). Though classical pathways, such as PTEN/PI3K/AKT, VEGF/VEGFR pathways, were found to involve in certain OS occurrence and progression, the intervening measure targeting these pathways fail to benefit all OS patients, indicating an urgency to seek the common targets of OS patients(Gill and Gorlick <xref ref-type="bibr" rid="CR2">2021</xref>). All living organisms, especially cancer cells, need to undergo energy metabolism, so targeting energy metabolism may be a viable approach for OS treatments(Porporato et al. <xref ref-type="bibr" rid="CR63">2018</xref>; Pavlova et al. <xref ref-type="bibr" rid="CR64">2022</xref>; Xia et al. <xref ref-type="bibr" rid="CR65">2021</xref>). Cuproptosis serves as an emerging cell death type targeting TCA cycle(Tsvetkov et al. <xref ref-type="bibr" rid="CR62">2022</xref>) and increasing evidence demonstrates that the TCA cycle is essential for the energy production and macromolecule synthesis of certain cancer cells with dysregulated oncogene and tumor suppressor expression(Anderson et al. <xref ref-type="bibr" rid="CR66">2018</xref>; Eniafe and Jiang <xref ref-type="bibr" rid="CR67">2021</xref>). Our study revealed the role of CYFIP1 in m7G modification and cuproptosis in OS, which ultimately triggers cuproptosis in OS cells, thereby suppressing the occurrence and progression of OS. Therefore, intervening in key targets of cuproptosis, which in turn interfere with energy metabolism and macromolecular synthesis, may be a feasible treatment method for OS. Additionally, given that the energy metabolism of cancer cells can be interconverted between glycolysis and oxidative phosphorylation(Pavlova et al. <xref ref-type="bibr" rid="CR64">2022</xref>), targeting the TCA cycle with the cuproptosis inducers might be utilized along with the glycolysis inhibitors to achieve more complete anticancer inhibition effects in the treatment of OS. This offers more potential drug combination regimens for the clinicians.</p><p id="Par66">In conclusion, our study demonstrates that CYFIP1 acts as a potent tumor suppressor in OS. The overexpression of CYFIP1 significantly inhibits OS cell proliferation and metastasis, while promoting apoptosis. Mechanistically, CYFIP1, in coordination with RNMT, stabilizes AURKAIP1 mRNA and enhances its translation, leading to the upregulation of FDX1 and the consequent OS cells cuproptosis. These findings provide a solid foundation for further research and potential therapeutic applications involving m7G modification and cuproptosis in the context of OS.</p></sec><sec id="Sec28" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10020_2025_1127_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="10020_2025_1127_MOESM2_ESM.xlsx"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>OS</term><def><p id="Par2">Osteosarcoma</p></def></def-item><def-item><term>m7G</term><def><p id="Par3">N7-methylguanosine</p></def></def-item><def-item><term>CYFIP1</term><def><p id="Par4">Cytoplasmic FMR1 Interacting Protein 1</p></def></def-item><def-item><term>WRC</term><def><p id="Par5">WAVE regulatory complex</p></def></def-item><def-item><term>TEM</term><def><p id="Par6">Transmission electron microscope</p></def></def-item><def-item><term>MMP</term><def><p id="Par7">Mitochondrial membrane potential</p></def></def-item><def-item><term>ROS</term><def><p id="Par8">Reactive oxygen species</p></def></def-item><def-item><term>TCA</term><def><p id="Par9">Tricarboxylic acid</p></def></def-item><def-item><term>PPI</term><def><p id="Par10">Protein-protein interaction</p></def></def-item><def-item><term>GSEA</term><def><p id="Par11">Gene set enrichment analysis</p></def></def-item><def-item><term>KEGG</term><def><p id="Par12">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>GO</term><def><p id="Par13">Gene Ontology</p></def></def-item><def-item><term>DEGs</term><def><p id="Par14">Differentially expressed genes</p></def></def-item><def-item><term>IHC</term><def><p id="Par15">Immunohistochemistry</p></def></def-item><def-item><term>ICC</term><def><p id="Par16">Immunocytochemistry</p></def></def-item><def-item><term>qPCR</term><def><p id="Par17">Quantitative polymerase chain reaction</p></def></def-item><def-item><term>FDR</term><def><p id="Par18">false discovery rate</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p><bold>Change history</bold></p><p>3/28/2025</p><p>The original online version of this article was revised: Fig. 3 appeared incorrectly and it has been updated.</p></fn><fn><p><bold>Change history</bold></p><p>4/7/2025</p><p>A Correction to this paper has been published: 10.1186/s10020-025-01185-7</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Xiangya hospital for their support of this work.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Wei Luo and Zili Lin selected the topic and revised the manuscript, Zili Lin, Ziyi Wu, Yizhe He, and Xiangya Li conducted the experiments, wrote the manuscript and made figure as well as table. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was funded by the Provincial Science and Technology Innovation Plan Project of Hunan (2023SK2023), the Provincial Science Foundation of Hunan (No. 2022JJ30075), the Joint funds of hospitals and enterprises (No. DK-KYHT-2022041901 and No. HFKC-KY-20220601; No. 15213659).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par67">This study was approved by the Animal Research Center of Central South University and the Ethics Committee of Xiangya Hospital of Central South University with ethics approval number 2021101013.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par68">All authors have given their final approval for the version to be published and have agreed on the journal to which the article has been submitted. The authors also accept responsibility for all aspects of the work.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par69">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Abekhoukh</surname><given-names>S</given-names></name><name><surname>Bardoni</surname><given-names>B</given-names></name></person-group><article-title>CYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome</article-title><source>Front Cell Neurosci</source><year>2014</year><volume>8</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.3389/fncel.2014.00081</pub-id><pub-id pub-id-type="pmid">24733999</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Abekhoukh S, Bardoni B. CYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome. Front Cell Neurosci. 2014;8:81. 10.3389/fncel.2014.00081.<pub-id pub-id-type="pmid">24733999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Abekhoukh</surname><given-names>S</given-names></name><etal/></person-group><article-title>New insights into the regulatory function of CYFIP1 in the context of WAVE- and FMRP-containing complexes</article-title><source>Dis Models Mech</source><year>2017</year><volume>10</volume><fpage>463</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1242/dmm.025809</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Abekhoukh S, et al. New insights into the regulatory function of CYFIP1 in the context of WAVE- and FMRP-containing complexes. Dis Models Mech. 2017;10:463&#x02013;74. 10.1242/dmm.025809.</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>A</given-names></name><name><surname>Martzen</surname><given-names>MR</given-names></name><name><surname>Phizicky</surname><given-names>EM</given-names></name></person-group><article-title>Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA</article-title><source>RNA (New York N Y)</source><year>2002</year><volume>8</volume><fpage>1253</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1017/s1355838202024019</pub-id><pub-id pub-id-type="pmid">12403464</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Alexandrov A, Martzen MR, Phizicky EM. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. RNA (New York N Y). 2002;8:1253&#x02013;66. 10.1017/s1355838202024019.<pub-id pub-id-type="pmid">12403464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>NM</given-names></name><name><surname>Mucka</surname><given-names>P</given-names></name><name><surname>Kern</surname><given-names>JG</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name></person-group><article-title>The emerging role and targetability of the TCA cycle in cancer metabolism</article-title><source>Protein Cell</source><year>2018</year><volume>9</volume><fpage>216</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s13238-017-0451-1</pub-id><pub-id pub-id-type="pmid">28748451</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9:216&#x02013;37. 10.1007/s13238-017-0451-1.<pub-id pub-id-type="pmid">28748451</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Arbour</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Treatment outcomes and clinical characteristics of patients with KRAS-G12C-Mutant Non-small Cell Lung Cancer</article-title><source>Clin cancer Research: Official J Am Association Cancer Res</source><year>2021</year><volume>27</volume><fpage>2209</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-20-4023</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Arbour KC, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-Mutant Non-small Cell Lung Cancer. Clin cancer Research: Official J Am Association Cancer Res. 2021;27:2209&#x02013;15. 10.1158/1078-0432.Ccr-20-4023.</mixed-citation></citation-alternatives></ref><ref id="CR57"><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Aregger</surname><given-names>M</given-names></name><etal/></person-group><article-title>CDK1-Cyclin B1 activates RNMT, coordinating mRNA Cap methylation with G1 phase transcription</article-title><source>Mol Cell</source><year>2016</year><volume>61</volume><fpage>734</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.02.008</pub-id><pub-id pub-id-type="pmid">26942677</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Aregger M, et al. CDK1-Cyclin B1 activates RNMT, coordinating mRNA Cap methylation with G1 phase transcription. Mol Cell. 2016;61:734&#x02013;46. 10.1016/j.molcel.2016.02.008.<pub-id pub-id-type="pmid">26942677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Bahr</surname><given-names>A</given-names></name><name><surname>Hankeln</surname><given-names>T</given-names></name><name><surname>Fiedler</surname><given-names>T</given-names></name><name><surname>Hegemann</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>ER</given-names></name></person-group><article-title>Molecular analysis of METTL1, a novel human methyltransferase-like gene with a high degree of phylogenetic conservation</article-title><source>Genomics</source><year>1999</year><volume>57</volume><fpage>424</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1006/geno.1999.5780</pub-id><pub-id pub-id-type="pmid">10329009</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Bahr A, Hankeln T, Fiedler T, Hegemann J, Schmidt ER. Molecular analysis of METTL1, a novel human methyltransferase-like gene with a high degree of phylogenetic conservation. Genomics. 1999;57:424&#x02013;8. 10.1006/geno.1999.5780.<pub-id pub-id-type="pmid">10329009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Barbieri</surname><given-names>I</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><article-title>Role of RNA modifications in cancer</article-title><source>Nat Rev Cancer</source><year>2020</year><volume>20</volume><fpage>303</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0253-2</pub-id><pub-id pub-id-type="pmid">32300195</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20:303&#x02013;22. 10.1038/s41568-020-0253-2.<pub-id pub-id-type="pmid">32300195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><mixed-citation publication-type="other">Bonaccorso CM et al. Fragile X mental retardation protein (FMRP) interacting proteins exhibit different expression patterns during development. 42, 15&#x02013;23, 10.1016/j.ijdevneu.2015.02.004 (2015).</mixed-citation></ref><ref id="CR55"><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Bramham</surname><given-names>CR</given-names></name><name><surname>Jensen</surname><given-names>KB</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name></person-group><article-title>Tuning specific translation in Cancer metastasis and synaptic memory: control at the MNK-eIF4E Axis</article-title><source>Trends Biochem Sci</source><year>2016</year><volume>41</volume><fpage>847</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2016.07.008</pub-id><pub-id pub-id-type="pmid">27527252</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Bramham CR, Jensen KB, Proud CG. Tuning specific translation in Cancer metastasis and synaptic memory: control at the MNK-eIF4E Axis. Trends Biochem Sci. 2016;41:847&#x02013;58. 10.1016/j.tibs.2016.07.008.<pub-id pub-id-type="pmid">27527252</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>4137</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0253-9</pub-id><pub-id pub-id-type="pmid">29706651</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Chang JW, et al. Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway. Oncogene. 2018;37:4137&#x02013;50. 10.1038/s41388-018-0253-9.<pub-id pub-id-type="pmid">29706651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><mixed-citation publication-type="other">Chen Z, et al. METTL1 promotes hepatocarcinogenesis via m(7) G tRNA modification-dependent translation control. Clin Translational Med. 2021;11(e661). 10.1002/ctm2.661.</mixed-citation></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C</given-names></name><name><surname>Shatkin</surname><given-names>AJ</given-names></name></person-group><article-title>Apoptosis and autophagy induction in mammalian cells by small interfering RNA knockdown of mRNA capping enzymes</article-title><source>Mol Cell Biol</source><year>2008</year><volume>28</volume><fpage>5829</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1128/mcb.00021-08</pub-id><pub-id pub-id-type="pmid">18678651</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chu C, Shatkin AJ. Apoptosis and autophagy induction in mammalian cells by small interfering RNA knockdown of mRNA capping enzymes. Mol Cell Biol. 2008;28:5829&#x02013;36. 10.1128/mcb.00021-08.<pub-id pub-id-type="pmid">18678651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>N(7)-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><fpage>3339</fpage><lpage>e33553338</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.07.003</pub-id><pub-id pub-id-type="pmid">34352206</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Dai Z, et al. N(7)-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Mol Cell. 2021;81:3339&#x02013;e33553338. 10.1016/j.molcel.2021.07.003.<pub-id pub-id-type="pmid">34352206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>De Rubeis</surname><given-names>S</given-names></name><etal/></person-group><article-title>CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation</article-title><source>Neuron</source><year>2013</year><volume>79</volume><fpage>1169</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.06.039</pub-id><pub-id pub-id-type="pmid">24050404</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">De Rubeis S, et al. CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron. 2013;79:1169&#x02013;82. 10.1016/j.neuron.2013.06.039.<pub-id pub-id-type="pmid">24050404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marino</surname><given-names>D</given-names></name><etal/></person-group><article-title>MD and Docking studies Reveal that the Functional switch of CYFIP1 is mediated by a Butterfly-like motion</article-title><source>J Chem Theory Comput</source><year>2015</year><volume>11</volume><fpage>3401</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1021/ct500431h</pub-id><pub-id pub-id-type="pmid">26575774</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Di Marino D, et al. MD and Docking studies Reveal that the Functional switch of CYFIP1 is mediated by a Butterfly-like motion. J Chem Theory Comput. 2015;11:3401&#x02013;10. 10.1021/ct500431h.<pub-id pub-id-type="pmid">26575774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Drummond</surname><given-names>DR</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Colman</surname><given-names>A</given-names></name></person-group><article-title>The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes</article-title><source>Nucleic Acids Res</source><year>1985</year><volume>13</volume><fpage>7375</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1093/nar/13.20.7375</pub-id><pub-id pub-id-type="pmid">3932972</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Drummond DR, Armstrong J, Colman A. The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes. Nucleic Acids Res. 1985;13:7375&#x02013;94. 10.1093/nar/13.20.7375.<pub-id pub-id-type="pmid">3932972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>S</given-names></name><name><surname>Lombardi</surname><given-names>O</given-names></name><name><surname>Lukoszek</surname><given-names>R</given-names></name><name><surname>Cowling</surname><given-names>VH</given-names></name></person-group><article-title>Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells</article-title><source>Open Biology</source><year>2019</year><volume>9</volume><fpage>190052</fpage><pub-id pub-id-type="doi">10.1098/rsob.190052</pub-id><pub-id pub-id-type="pmid">30991934</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Dunn S, Lombardi O, Lukoszek R, Cowling VH. Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells. Open Biology. 2019;9:190052. 10.1098/rsob.190052.<pub-id pub-id-type="pmid">30991934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Dziunycz</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>CYFIP1 is directly controlled by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><fpage>e0173000</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0173000</pub-id><pub-id pub-id-type="pmid">28410392</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Dziunycz PJ, et al. CYFIP1 is directly controlled by NOTCH1 and down-regulated in cutaneous squamous cell carcinoma. PLoS ONE. 2017;12:e0173000. 10.1371/journal.pone.0173000.<pub-id pub-id-type="pmid">28410392</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Eniafe</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name></person-group><article-title>The functional roles of TCA cycle metabolites in cancer</article-title><source>Oncogene</source><year>2021</year><volume>40</volume><fpage>3351</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01639-8</pub-id><pub-id pub-id-type="pmid">33864000</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Eniafe J, Jiang S. The functional roles of TCA cycle metabolites in cancer. Oncogene. 2021;40:3351&#x02013;63. 10.1038/s41388-020-01639-8.<pub-id pub-id-type="pmid">33864000</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Fresquet</surname><given-names>V</given-names></name><etal/></person-group><article-title>Endogenous retroelement activation by epigenetic therapy reverses the Warburg Effect and elicits mitochondrial-mediated Cancer cell death</article-title><source>Cancer Discov</source><year>2021</year><volume>11</volume><fpage>1268</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.Cd-20-1065</pub-id><pub-id pub-id-type="pmid">33355179</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Fresquet V, et al. Endogenous retroelement activation by epigenetic therapy reverses the Warburg Effect and elicits mitochondrial-mediated Cancer cell death. Cancer Discov. 2021;11:1268&#x02013;85. 10.1158/2159-8290.Cd-20-1065.<pub-id pub-id-type="pmid">33355179</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Furuichi</surname><given-names>Y</given-names></name><name><surname>LaFiandra</surname><given-names>A</given-names></name><name><surname>Shatkin</surname><given-names>AJ</given-names></name></person-group><article-title>5&#x02019;-Terminal structure and mRNA stability</article-title><source>Nature</source><year>1977</year><volume>266</volume><fpage>235</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/266235a0</pub-id><pub-id pub-id-type="pmid">557727</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Furuichi Y, LaFiandra A, Shatkin AJ. 5&#x02019;-Terminal structure and mRNA stability. Nature. 1977;266:235&#x02013;9. 10.1038/266235a0.<pub-id pub-id-type="pmid">557727</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>J</given-names></name><name><surname>Gorlick</surname><given-names>R</given-names></name></person-group><article-title>Advancing therapy for osteosarcoma</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><volume>18</volume><fpage>609</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00519-8</pub-id><pub-id pub-id-type="pmid">34131316</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18:609&#x02013;24. 10.1038/s41571-021-00519-8.<pub-id pub-id-type="pmid">34131316</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><etal/></person-group><article-title>N(7)-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>1478</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-29125-7</pub-id><pub-id pub-id-type="pmid">35304469</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Han H, et al. N(7)-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis. Nat Commun. 2022;13:1478. 10.1038/s41467-022-29125-7.<pub-id pub-id-type="pmid">35304469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name></person-group><article-title>N(7)-methylguanosine (m(7)G) tRNA modification: a novel autophagy modulator in cancer</article-title><source>Autophagy</source><year>2023</year><volume>19</volume><fpage>360</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1080/15548627.2022.2077551</pub-id><pub-id pub-id-type="pmid">35574843</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Han H, Zheng S, Lin S. N(7)-methylguanosine (m(7)G) tRNA modification: a novel autophagy modulator in cancer. Autophagy. 2023;19:360&#x02013;2. 10.1080/15548627.2022.2077551.<pub-id pub-id-type="pmid">35574843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><etal/></person-group><article-title>M(7)G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma</article-title><source>Oncogene</source><year>2024</year><volume>43</volume><fpage>341</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/s41388-023-02882-5</pub-id><pub-id pub-id-type="pmid">38040806</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">He M, et al. M(7)G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma. Oncogene. 2024;43:341&#x02013;53. 10.1038/s41388-023-02882-5.<pub-id pub-id-type="pmid">38040806</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Kansara</surname><given-names>M</given-names></name><name><surname>Teng</surname><given-names>MW</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Thomas</surname><given-names>DM</given-names></name></person-group><article-title>Translational biology of osteosarcoma</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><fpage>722</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/nrc3838</pub-id><pub-id pub-id-type="pmid">25319867</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14:722&#x02013;35. 10.1038/nrc3838.<pub-id pub-id-type="pmid">25319867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><mixed-citation publication-type="other">Key J, et al. CLPP depletion causes Diplotene arrest; underlying Testis mitochondrial dysfunction occurs with Accumulation of Perrault Proteins ERAL1, PEO1, and HARS2. Cells. 2022;12. 10.3390/cells12010052.</mixed-citation></ref><ref id="CR61"><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Koc</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Identification and characterization of CHCHD1, AURKAIP1, and CRIF1 as new members of the mammalian mitochondrial ribosome</article-title><source>Front Physiol</source><year>2013</year><volume>4</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.3389/fphys.2013.00183</pub-id><pub-id pub-id-type="pmid">23908630</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Koc EC, et al. Identification and characterization of CHCHD1, AURKAIP1, and CRIF1 as new members of the mammalian mitochondrial ribosome. Front Physiol. 2013;4:183. 10.3389/fphys.2013.00183.<pub-id pub-id-type="pmid">23908630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Konarska</surname><given-names>MM</given-names></name><name><surname>Padgett</surname><given-names>RA</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name></person-group><article-title>Recognition of cap structure in splicing in vitro of mRNA precursors</article-title><source>Cell</source><year>1984</year><volume>38</volume><fpage>731</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(84)90268-x</pub-id><pub-id pub-id-type="pmid">6567484</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Konarska MM, Padgett RA, Sharp PA. Recognition of cap structure in splicing in vitro of mRNA precursors. Cell. 1984;38:731&#x02013;6. 10.1016/0092-8674(84)90268-x.<pub-id pub-id-type="pmid">6567484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Izaurralde</surname><given-names>E</given-names></name></person-group><article-title>The role of the cap structure in RNA processing and nuclear export</article-title><source>Eur J Biochem</source><year>1997</year><volume>247</volume><fpage>461</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1997.00461.x</pub-id><pub-id pub-id-type="pmid">9266685</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lewis JD, Izaurralde E. The role of the cap structure in RNA processing and nuclear export. Eur J Biochem. 1997;247:461&#x02013;9. 10.1111/j.1432-1033.1997.00461.x.<pub-id pub-id-type="pmid">9266685</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Limaye</surname><given-names>AJ</given-names></name><name><surname>Whittaker</surname><given-names>MK</given-names></name><name><surname>Bendzunas</surname><given-names>GN</given-names></name><name><surname>Cowell</surname><given-names>JK</given-names></name><name><surname>Kennedy</surname><given-names>EJ</given-names></name></person-group><article-title>Targeting the WASF3 complex to suppress metastasis</article-title><source>Pharmacol Res</source><year>2022</year><volume>182</volume><fpage>106302</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106302</pub-id><pub-id pub-id-type="pmid">35691539</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Limaye AJ, Whittaker MK, Bendzunas GN, Cowell JK, Kennedy EJ. Targeting the WASF3 complex to suppress metastasis. Pharmacol Res. 2022;182:106302. 10.1016/j.phrs.2022.106302.<pub-id pub-id-type="pmid">35691539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Lindstrom</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Dual roles for Spt5 in pre-mRNA processing and transcription elongation revealed by identification of Spt5-associated proteins</article-title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><fpage>1368</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1128/mcb.23.4.1368-1378.2003</pub-id><pub-id pub-id-type="pmid">12556496</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lindstrom DL, et al. Dual roles for Spt5 in pre-mRNA processing and transcription elongation revealed by identification of Spt5-associated proteins. Mol Cell Biol. 2003;23:1368&#x02013;78. 10.1128/mcb.23.4.1368-1378.2003.<pub-id pub-id-type="pmid">12556496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><mixed-citation publication-type="other">Love MI, Huber W, Anders S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(550). 10.1186/s13059-014-0550-8.</mixed-citation></ref><ref id="CR11"><mixed-citation publication-type="other">Luo Y, et al. The potential role of N(7)-methylguanosine (m7G) in cancer. J Hematol Oncol. 2022;15. 10.1186/s13045-022-01285-5.</mixed-citation></ref><ref id="CR52"><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><etal/></person-group><article-title>METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression</article-title><source>Mol Therapy: J Am Soc Gene Therapy</source><year>2021</year><volume>29</volume><fpage>3422</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.08.005</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Ma J, et al. METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression. Mol Therapy: J Am Soc Gene Therapy. 2021;29:3422&#x02013;35. 10.1016/j.ymthe.2021.08.005.</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>Helman</surname><given-names>LJ</given-names></name></person-group><article-title>New Horizons in the Treatment of Osteosarcoma</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>2066</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2103423</pub-id><pub-id pub-id-type="pmid">34818481</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021;385:2066&#x02013;76. 10.1056/NEJMra2103423.<pub-id pub-id-type="pmid">34818481</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><mixed-citation publication-type="other">Merrick WC, Pavitt GD. Protein Synthesis Initiation in Eukaryotic Cells. <italic>Cold Spring Harbor perspectives in biology</italic> 10. 10.1101/cshperspect.a033092 (2018).</mixed-citation></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>KG</given-names></name><name><surname>Park</surname><given-names>P</given-names></name><name><surname>Manley</surname><given-names>JL</given-names></name></person-group><article-title>A nuclear micrococcal-sensitive, ATP-dependent exoribonuclease degrades uncapped but not capped RNA substrates</article-title><source>Nucleic Acids Res</source><year>1991</year><volume>19</volume><fpage>2685</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/nar/19.10.2685</pub-id><pub-id pub-id-type="pmid">1710342</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Murthy KG, Park P, Manley JL. A nuclear micrococcal-sensitive, ATP-dependent exoribonuclease degrades uncapped but not capped RNA substrates. Nucleic Acids Res. 1991;19:2685&#x02013;92. 10.1093/nar/19.10.2685.<pub-id pub-id-type="pmid">1710342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Muthukrishnan</surname><given-names>S</given-names></name><name><surname>Both</surname><given-names>GW</given-names></name><name><surname>Furuichi</surname><given-names>Y</given-names></name><name><surname>Shatkin</surname><given-names>AJ</given-names></name></person-group><article-title>5&#x02019;-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation</article-title><source>Nature</source><year>1975</year><volume>255</volume><fpage>33</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/255033a0</pub-id><pub-id pub-id-type="pmid">165427</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Muthukrishnan S, Both GW, Furuichi Y, Shatkin AJ. 5&#x02019;-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation. Nature. 1975;255:33&#x02013;7. 10.1038/255033a0.<pub-id pub-id-type="pmid">165427</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Napoli</surname><given-names>I</given-names></name><etal/></person-group><article-title>The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP</article-title><source>Cell</source><year>2008</year><volume>134</volume><fpage>1042</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.07.031</pub-id><pub-id pub-id-type="pmid">18805096</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Napoli I, et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell. 2008;134:1042&#x02013;54. 10.1016/j.cell.2008.07.031.<pub-id pub-id-type="pmid">18805096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Orellana</surname><given-names>EA</given-names></name><etal/></person-group><article-title>METTL1-mediated m(7)G modification of Arg-TCT tRNA drives oncogenic transformation</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><fpage>3323</fpage><lpage>e33383314</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.06.031</pub-id><pub-id pub-id-type="pmid">34352207</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Orellana EA, et al. METTL1-mediated m(7)G modification of Arg-TCT tRNA drives oncogenic transformation. Mol Cell. 2021;81:3323&#x02013;e33383314. 10.1016/j.molcel.2021.06.031.<pub-id pub-id-type="pmid">34352207</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Identification and characterization of the Interaction between the Methyl-7-Guanosine Cap Maturation enzyme RNMT and the Cap-binding protein eIF4E</article-title><source>J Mol Biol</source><year>2022</year><volume>434</volume><fpage>167451</fpage><pub-id pub-id-type="doi">10.1016/j.jmb.2022.167451</pub-id><pub-id pub-id-type="pmid">35026230</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Osborne MJ, et al. Identification and characterization of the Interaction between the Methyl-7-Guanosine Cap Maturation enzyme RNMT and the Cap-binding protein eIF4E. J Mol Biol. 2022;434:167451. 10.1016/j.jmb.2022.167451.<pub-id pub-id-type="pmid">35026230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Pandolfini</surname><given-names>L</given-names></name><etal/></person-group><article-title>METTL1 promotes let-7 MicroRNA Processing via m7G methylation</article-title><source>Mol Cell</source><year>2019</year><volume>74</volume><fpage>1278</fpage><lpage>e12901279</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.03.040</pub-id><pub-id pub-id-type="pmid">31031083</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Pandolfini L, et al. METTL1 promotes let-7 MicroRNA Processing via m7G methylation. Mol Cell. 2019;74:1278&#x02013;e12901279. 10.1016/j.molcel.2019.03.040.<pub-id pub-id-type="pmid">31031083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlova</surname><given-names>NN</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>The hallmarks of cancer metabolism: still emerging</article-title><source>Cell Metabol</source><year>2022</year><volume>34</volume><fpage>355</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.01.007</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metabol. 2022;34:355&#x02013;77. 10.1016/j.cmet.2022.01.007.</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Shuman</surname><given-names>S</given-names></name></person-group><article-title>Interactions between fission yeast mRNA capping enzymes and elongation factor Spt5</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>19639</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200015200</pub-id><pub-id pub-id-type="pmid">11893740</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Pei Y, Shuman S. Interactions between fission yeast mRNA capping enzymes and elongation factor Spt5. J Biol Chem. 2002;277:19639&#x02013;48. 10.1074/jbc.M200015200.<pub-id pub-id-type="pmid">11893740</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Porporato</surname><given-names>PE</given-names></name><name><surname>Filigheddu</surname><given-names>N</given-names></name><name><surname>Pedro</surname><given-names>JMB</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><article-title>Mitochondrial metabolism and cancer</article-title><source>Cell Res</source><year>2018</year><volume>28</volume><fpage>265</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/cr.2017.155</pub-id><pub-id pub-id-type="pmid">29219147</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265&#x02013;80. 10.1038/cr.2017.155.<pub-id pub-id-type="pmid">29219147</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR1"><mixed-citation publication-type="other">Ritter J, Bielack SS, Osteosarcoma. Annals Oncology: Official J Eur Soc Med Oncol. 2010;21. 10.1093/annonc/mdq276. Suppl 7, vii320-325.</mixed-citation></ref><ref id="CR46"><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>D</given-names></name><etal/></person-group><article-title>Epigenetics: roles and therapeutic implications of non-coding RNA modifications in human cancers</article-title><source>Mol Therapy Nucleic Acids</source><year>2021</year><volume>25</volume><fpage>67</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2021.04.021</pub-id><pub-id pub-id-type="pmid">34188972</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Rong D, et al. Epigenetics: roles and therapeutic implications of non-coding RNA modifications in human cancers. Mol Therapy Nucleic Acids. 2021;25:67&#x02013;82. 10.1016/j.omtn.2021.04.021.<pub-id pub-id-type="pmid">34188972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Roundtree</surname><given-names>IA</given-names></name><name><surname>Evans</surname><given-names>ME</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>C</given-names></name></person-group><article-title>Dynamic RNA modifications in Gene expression regulation</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>1187</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.045</pub-id><pub-id pub-id-type="pmid">28622506</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in Gene expression regulation. Cell. 2017;169:1187&#x02013;200. 10.1016/j.cell.2017.05.045.<pub-id pub-id-type="pmid">28622506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimotohno</surname><given-names>K</given-names></name><name><surname>Kodama</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>J</given-names></name><name><surname>Miura</surname><given-names>KI</given-names></name></person-group><article-title>Importance of 5&#x02019;-terminal blocking structure to stabilize mRNA in eukaryotic protein synthesis</article-title><source>Proc Natl Acad Sci USA</source><year>1977</year><volume>74</volume><fpage>2734</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1073/pnas.74.7.2734</pub-id><pub-id pub-id-type="pmid">197518</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Shimotohno K, Kodama Y, Hashimoto J, Miura KI. Importance of 5&#x02019;-terminal blocking structure to stabilize mRNA in eukaryotic protein synthesis. Proc Natl Acad Sci USA. 1977;74:2734&#x02013;8. 10.1073/pnas.74.7.2734.<pub-id pub-id-type="pmid">197518</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Cyfip1 is a putative invasion suppressor in epithelial cancers</article-title><source>Cell</source><year>2009</year><volume>137</volume><fpage>1047</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.013</pub-id><pub-id pub-id-type="pmid">19524508</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Silva JM, et al. Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell. 2009;137:1047&#x02013;61. 10.1016/j.cell.2009.04.013.<pub-id pub-id-type="pmid">19524508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>B</given-names></name><etal/></person-group><article-title>m7GHub: deciphering the location, regulation and pathogenesis of internal mRNA N7-methylguanosine (m7G) sites in human</article-title><source>Bioinf (Oxford England)</source><year>2020</year><volume>36</volume><fpage>3528</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa178</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Song B, et al. m7GHub: deciphering the location, regulation and pathogenesis of internal mRNA N7-methylguanosine (m7G) sites in human. Bioinf (Oxford England). 2020;36:3528&#x02013;36. 10.1093/bioinformatics/btaa178.</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanska</surname><given-names>B</given-names></name><etal/></person-group><article-title>Genome-wide study of hypomethylated and induced genes in patients with liver cancer unravels novel anticancer targets</article-title><source>Clin cancer Research: Official J Am Association Cancer Res</source><year>2014</year><volume>20</volume><fpage>3118</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-13-0283</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Stefanska B, et al. Genome-wide study of hypomethylated and induced genes in patients with liver cancer unravels novel anticancer targets. Clin cancer Research: Official J Am Association Cancer Res. 2014;20:3118&#x02013;32. 10.1158/1078-0432.Ccr-13-0283.</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epigenetic induction of mitochondrial fission is required for maintenance of Liver Cancer-initiating cells</article-title><source>Cancer Res</source><year>2021</year><volume>81</volume><fpage>3835</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.Can-21-0436</pub-id><pub-id pub-id-type="pmid">34049973</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Tang M, et al. Epigenetic induction of mitochondrial fission is required for maintenance of Liver Cancer-initiating cells. Cancer Res. 2021;81:3835&#x02013;48. 10.1158/0008-5472.Can-21-0436.<pub-id pub-id-type="pmid">34049973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The WASF3-NCKAP1-CYFIP1 complex is essential for breast Cancer metastasis</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>5133</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.Can-16-0562</pub-id><pub-id pub-id-type="pmid">27432794</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Teng Y, et al. The WASF3-NCKAP1-CYFIP1 complex is essential for breast Cancer metastasis. Cancer Res. 2016a;76:5133&#x02013;42. 10.1158/0008-5472.Can-16-0562.<pub-id pub-id-type="pmid">27432794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses Cancer Cell Invasion</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><fpage>965</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.Can-15-1680</pub-id><pub-id pub-id-type="pmid">26676744</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Teng Y, et al. Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses Cancer Cell Invasion. Cancer Res. 2016b;76:965&#x02013;73. 10.1158/0008-5472.Can-15-1680.<pub-id pub-id-type="pmid">26676744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>QH</given-names></name><etal/></person-group><article-title>METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN</article-title><source>J Mol Med</source><year>2019</year><volume>97</volume><fpage>1535</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s00109-019-01830-9</pub-id><pub-id pub-id-type="pmid">31463732</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tian QH, et al. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN. J Mol Med. 2019;97:1535&#x02013;45. 10.1007/s00109-019-01830-9.<pub-id pub-id-type="pmid">31463732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Trotman</surname><given-names>JB</given-names></name><name><surname>Giltmier</surname><given-names>AJ</given-names></name><name><surname>Mukherjee</surname><given-names>C</given-names></name><name><surname>Schoenberg</surname><given-names>DR</given-names></name></person-group><article-title>RNA guanine-7 methyltransferase catalyzes the methylation of cytoplasmically recapped RNAs</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><fpage>10726</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx801</pub-id><pub-id pub-id-type="pmid">28981715</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Trotman JB, Giltmier AJ, Mukherjee C, Schoenberg DR. RNA guanine-7 methyltransferase catalyzes the methylation of cytoplasmically recapped RNAs. Nucleic Acids Res. 2017;45:10726&#x02013;39. 10.1093/nar/gkx801.<pub-id pub-id-type="pmid">28981715</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsvetkov</surname><given-names>P</given-names></name><etal/></person-group><article-title>Copper induces cell death by targeting lipoylated TCA cycle proteins</article-title><source>Sci (New York N Y)</source><year>2022</year><volume>375</volume><fpage>1254</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.abf0529</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Tsvetkov P, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Sci (New York N Y). 2022;375:1254&#x02013;61. 10.1126/science.abf0529.</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>METTL1/WDR4-mediated tRNA m(7)G modification and mRNA translation control promote oncogenesis and doxorubicin resistance</article-title><source>Oncogene</source><year>2023</year><volume>42</volume><fpage>1900</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41388-023-02695-6</pub-id><pub-id pub-id-type="pmid">37185458</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wang Z, et al. METTL1/WDR4-mediated tRNA m(7)G modification and mRNA translation control promote oncogenesis and doxorubicin resistance. Oncogene. 2023;42:1900&#x02013;12. 10.1038/s41388-023-02695-6.<pub-id pub-id-type="pmid">37185458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Livingston</surname><given-names>JA</given-names></name></person-group><article-title>Genomics and the Immune Landscape of Osteosarcoma</article-title><source>Adv Exp Med Biol</source><year>2020</year><volume>1258</volume><fpage>21</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-43085-6_2</pub-id><pub-id pub-id-type="pmid">32767232</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wu CC, Livingston JA. Genomics and the Immune Landscape of Osteosarcoma. Adv Exp Med Biol. 2020;1258:21&#x02013;36. 10.1007/978-3-030-43085-6_2.<pub-id pub-id-type="pmid">32767232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>L</given-names></name><etal/></person-group><article-title>The cancer metabolic reprogramming and immune response</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01316-8</pub-id><pub-id pub-id-type="pmid">33546704</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Xia L, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28. 10.1186/s12943-021-01316-8.<pub-id pub-id-type="pmid">33546704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>JC</given-names></name></person-group><article-title>Internal m7G methylation: a novel epitranscriptomic contributor in brain development and diseases</article-title><source>Mol Therapy Nucleic Acids</source><year>2023</year><volume>31</volume><fpage>295</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2023.01.003</pub-id><pub-id pub-id-type="pmid">36726408</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Xia X, Wang Y, Zheng JC. Internal m7G methylation: a novel epitranscriptomic contributor in brain development and diseases. Mol Therapy Nucleic Acids. 2023;31:295&#x02013;308. 10.1016/j.omtn.2023.01.003.<pub-id pub-id-type="pmid">36726408</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Arabidopsis DXO1 activates RNMT1 to methylate the mRNA guanosine cap</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>202</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-35903-8</pub-id><pub-id pub-id-type="pmid">36639378</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Xiao C, et al. Arabidopsis DXO1 activates RNMT1 to methylate the mRNA guanosine cap. Nat Commun. 2023;14:202. 10.1038/s41467-023-35903-8.<pub-id pub-id-type="pmid">36639378</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>TXNIP inhibits the progression of osteosarcoma through DDIT4-mediated mTORC1 suppression</article-title><source>Am J cancer Res</source><year>2022</year><volume>12</volume><fpage>3760</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">36119812</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Yuan Y, et al. TXNIP inhibits the progression of osteosarcoma through DDIT4-mediated mTORC1 suppression. Am J cancer Res. 2022;12:3760&#x02013;79.<pub-id pub-id-type="pmid">36119812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><mixed-citation publication-type="other">Zhao B, Roundtree I, He CJ. N. r. M. c. b. post-transcriptional gene regulation by mRNA modifications. 18, 31&#x02013;42, 10.1038/nrm.2016.132 (2017).</mixed-citation></ref></ref-list></back></article>